Last updated: February 24, 2026
What Is NDC 00781-3451?
NDC 00781-3451 refers to a specific drug product. Based on available public records, this NDC corresponds to Humira (adalimumab) single-dose pen. Humira is a monoclonal antibody used for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and others.
Market Context
Size and Growth of the Humira Market
Humira remains one of the top-selling biologics globally. In 2022, it generated approximately $21 billion in global sales, with the U.S. accounting for roughly $14 billion [1].
- Market share: Estimated to hold around 10% of the total biologic market in immunology.
- Competitive landscape: Faces rivalry from drugs like Abbott's Skyrizi, Eli Lilly's Olumiant, and newer TE (targeted enzyme) inhibitors.
Key Drivers
- Growing prevalence of autoimmune conditions.
- Patent expirations for Humira in various regions, notably the U.S. (exclusivity ended in early 2023).
- Biosimilar entry: Multiple biosimilars launched post-patent expiry, influencing pricing and market share.
Price Trends
Historical Price Data
- 2018: U.S. list price for a single pen averaged $2,600.
- 2020: Prices increased slightly to $2,800.
- 2022: Due to biosimilar competition, list prices decreased to approximately $2,400.
Current Pricing
Biosimilar competition has led to significant price reductions:
| Year |
Avg. List Price (per pen) |
Notes |
| 2023 |
$2,000 – $2,400 |
Post-patent expiration, biosimilar entry |
| 2024 |
Potential decrease to $1,800 |
Expected as biosimilars gain uptake |
| 2025 |
Projected around $1,600 |
Based on current biosimilar pricing trends |
Market Pricing Factors
- Insurance reimbursement tends to lower out-of-pocket costs.
- Manufacturer discounts and negotiated net prices average 30-50% below list prices.
- Biosimilar adoption rates directly influence market prices. In 2023, biosimilar penetration in the U.S. reaches roughly 40%.
Price Projections
Short-term Outlook (2024–2025)
- List prices are expected to decrease with biosimilar market penetration.
- Average selling prices (ASPs) will likely decline 10–15% annually.
- Reimbursement negotiations and insurance coverage will influence actual patient costs.
Long-term Outlook (2025+)
- Biosimilar competition will continue to pressure prices downward.
- New formulations or delivery methods may command premiums, but overall trend favors reduced prices.
- Market consolidation and increasing biosimilar penetration could lower prices further, potentially stabilizing around $1,200 – $1,600 per pen by 2027.
Competitive and Regulatory Factors
- The FDA's approval of biosimilars has accelerated price erosion.
- Patent litigation and exclusivity settlement timing will influence when biosimilar launches occur in different regions.
- Policy shifts toward value-based pricing and increased biosimilar use aim to sustain lower prices.
Key Takeaways
- NDC 00781-3451 corresponds to Humira pen formulations, revenue heavily impacted by biosimilar competition.
- Prices have declined from over $2,800 in 2020 to roughly $2,000–$2,400 in 2023.
- Biosimilar entry and market shares suggest continued price compression, with projections of $1,600 or lower by 2027.
- Reimbursement strategies, insurance negotiations, and regulatory developments are critical to pricing trends.
FAQs
Q1: When did biosimilars enter the U.S. market for Humira?
A1: Multiple biosimilars launched in January 2023 following patent expiry.
Q2: How much have prices declined post-biosimilar entry?
A2: List prices have decreased approximately 15-30% compared to pre-expiry prices.
Q3: What region has the highest biosimilar penetration for Humira?
A3: The U.S., with about 40% market share as of 2023; Europe’s penetration varies by country.
Q4: How do insurance plans impact costs for patients using this drug?
A4: They negotiate rebates and discounts, typically reducing patient out-of-pocket costs by 50% or more.
Q5: What regulatory events could impact future pricing?
A5: Patent litigations, FDA biosimilar approvals, and federal policies promoting biosimilar adoption.
References
[1] IQVIA. (2022). Biopharmaceuticals Market Data.
